I'm confused about the numbers in this paper. The say there were three categories--cases of PCF suspected by the reporter but apparently not confirmed by CACRC (262 cases); suspected by the reporter AND confirmed by CACRC (147); and then a third category of confirmed PCF by the CACRC but for...
They found the funding to assess the BPS approach to homebound with the failed FINE study, the "sister trial" to PACE. There needs to be similar funding for biomedical studies, so they have the bandwidth to collect samples etc from homebound.
you're right. I had glanced at it and misread it. But I'm from the country that has rejected vaccines. So, you know, everything I say is up for grabs and nothing can be taken for granted.
it's a case series of patients, not a trial. I assume a trial might come next? I think case studies can be useful and interesting for ideas but obviously are not comparable to evidence from a trial.
I sent a letter to the journal.
https://virology.ws/2025/08/27/trial-by-error-letter-to-eclinicalmedicine-about-exercise-recommendations-in-flawed-meta-analysis-of-long-covid-interventions/
I checked in with Chris about this. He pointed out that the number comes from a different paper that found a point prevalence estimate (current prevalence, as opposed to lifetime prevalence) of 410,000. So yes, the lifetime prevalence figure would not represent current (point) prevalence. but...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.